Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study CR9112792: A 12-month, Randomized, Double-blind, Parallel-group, Placebo and Active-controlled Dose-range Finding Study of the Efficacy and Safety of SB-751689 in Post-menopausal Women With Osteoporosis.

Trial Profile

Study CR9112792: A 12-month, Randomized, Double-blind, Parallel-group, Placebo and Active-controlled Dose-range Finding Study of the Efficacy and Safety of SB-751689 in Post-menopausal Women With Osteoporosis.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Ronacaleret (Primary) ; Alendronic acid; Teriparatide
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 08 May 2010 Interim results were reported at the 2010 IOF World Congress on Osteoporosis and 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.
    • 08 May 2010 Results were reported at the 2010 IOF World Congress on Osteoporosis and 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top